{"id":"NCT00364351","sponsor":"Genzyme, a Sanofi Company","briefTitle":"Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy","officialTitle":"A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2008-09","completion":"2016-11","firstPosted":"2006-08-15","resultsPosted":"2011-05-24","lastUpdate":"2018-01-25"},"enrollment":1574,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Non Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Vandetanib","otherNames":["ZD6474","ZACTIMA™"]},{"type":"DRUG","name":"Erlotinib","otherNames":["Tarceva®"]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib","primaryOutcome":{"measure":"Progression-Free Survival (PFS)","timeFrame":"progressionRECIST tumour assessments carried out every 4 weeks up to week 16 then every 8 weeks thereafter from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first, assessed.","effectByArm":[{"arm":"Vandetanib","deltaMin":11.3,"sd":null},{"arm":"Erlotinib","deltaMin":8.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":153,"countries":["United States","Argentina","Australia","Brazil","Canada","China","Denmark","France","Germany","Hong Kong","India","Indonesia","Italy","Mexico","Netherlands","Norway","Philippines","South Korea","Spain","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["21282542","40785488","25881079"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=347&filename=Vandetanib_study_57_ZEST_CSP_redacted_SECURE.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":197,"n":623},"commonTop":["Diarrhoea","Rash","Nausea","Anorexia","Fatigue"]}}